SFL Pharma places prescription drugs onto the Swiss market, with a special focus on orphan drugs. Rare (or "orphan") diseases are life-threatening or chronically debilitating diseases that occur in less than 5 in 10,000 people in the Swiss community. There are approximately 7,000 rare diseases that may affect around 500,000 people in Switzerland.


More information on Galafold is available on the Swissmedic website:

Lysosomal Storage Disorders

Among orphan diseases, lysosomal storage disorders (LSD) pose a subgroup of 50 rare, medical conditions that affect approximately 10,000 people worldwide. LSDs are inherited metabolic disorders that are caused by a lack of specific enzymes that are responsible for the disposal of cellular substances in so-called lysosomes. As a result, these substances accumulate and cause toxicity in different organ systems such as kidney, muscle, lung, heart and brain. LSDs are severe, life-threatening diseases and put a heavy burden on patients, their caregivers and the healthcare system.